FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312129162> ?p ?o ?g. }

• W4312129162 abstract "Abstract Background Other iatrogenic immunodeficiency-associated (OIIA) T- and natural killer (NK)-cell lymphoproliferative disorders (TNK-LPDs) are rare in patients with rheumatoid arthritis (RA). Methods We investigated the clinicopathological characteristics, Epstein–Barr virus (EBV) infection, genetic findings, therapeutic response, and prognostic factors in 21 RA patients with OIIA TNK-LPDs and compared these with those of 39 with OIIA B-cell LPDs (B-LPDs) and 22 with non-OIIA B-LPDs. Results Immunohistologically, 11 patients (52%) showed CD4+ T-LPDs, and 7 had a T follicular helper (TFH) phenotype. The other nine patients (43%) showed CD8+ T-LPDs, and the remaining one (5%) had features of CD3+ CD4− CD8− nasal type TNK-cell lymphoma. CD30+, p53+, and CMYC+ atypical lymphocytes were identified in seven (33%), eight (38%), and five (24%) patients, respectively. In situ hybridisation detected EBV-encoded RNA (EBER) + large atypical lymphocytes in five patients (24%). Nine of 17 patients (53%) showed clonal peaks of TCRγ by polymerase chain reaction. Withdrawal of MTX and biologic drugs was effective in 12 patients (57%), and 8 (38%) received chemotherapies. Two patients with TFH+ or EBV+ CD4+ CD30+ large cell peripheral T-cell lymphoma, one with CD8+ systemic anaplastic large cell lymphoma, and two with systemic EBV+ CD8+ T-cell lymphoma of childhood showed a lethal progressive clinical course within 13 months. Moreover, > 500 U/L LDH, large atypical lymphocytes, expression of CD30, p53, and CMYC, and EBER+ atypical lymphocytes were significantly poor prognostic factors for overall survival ( p < 0.05). Median interval from RA onset to OIIA TNK-LPDs was 72 months, which was shorter than 166 months in OIIA B-LPDs ( p = 0.003). EBV+ atypical and reactive lymphocytes were frequently found in 15 patients with OIIA TNK-LPDs (71%), in 27 with OIIA B-LPDs (69%), and only in 3 with non-OIIA B-LPDs (14%). Conclusions OIIA TNK-LPDs occurred in early phase of RA, compared with OIIA B-LPDs, and occasionally showed a lethal progressive clinical course. Detection of OIIA TNK-LPD patients with poor prognostic factors is necessary. EBV infection in immunosuppressed patients due to persistent RA, MTX, and biologic drugs may play a role in forming the tumour microenvironment and lymphomagenesis of TNK-LPDs." @default.
• W4312129162 created "2023-01-04" @default.
• W4312129162 creator A5018555044 @default.
• W4312129162 creator A5026480264 @default.
• W4312129162 creator A5038250239 @default.
• W4312129162 creator A5041701016 @default.
• W4312129162 creator A5049515542 @default.
• W4312129162 creator A5055137050 @default.
• W4312129162 creator A5060126327 @default.
• W4312129162 creator A5072689759 @default.
• W4312129162 creator A5080684289 @default.
• W4312129162 creator A5083470582 @default.
• W4312129162 creator A5085561415 @default.
• W4312129162 date "2022-12-22" @default.
• W4312129162 modified "2023-10-16" @default.
• W4312129162 title "Clinicopathological findings, prognosis, and Epstein–Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders" @default.
• W4312129162 cites W1967262271 @default.
• W4312129162 cites W1967345289 @default.
• W4312129162 cites W2016694012 @default.
• W4312129162 cites W2017497764 @default.
• W4312129162 cites W2020094108 @default.
• W4312129162 cites W2031986546 @default.
• W4312129162 cites W2044533696 @default.
• W4312129162 cites W2047505662 @default.
• W4312129162 cites W2051436390 @default.
• W4312129162 cites W2056277576 @default.
• W4312129162 cites W2060574669 @default.
• W4312129162 cites W2080382012 @default.
• W4312129162 cites W2135060207 @default.
• W4312129162 cites W2322203441 @default.
• W4312129162 cites W2385313902 @default.
• W4312129162 cites W2557045302 @default.
• W4312129162 cites W2613388345 @default.
• W4312129162 cites W2783157660 @default.
• W4312129162 cites W2806188167 @default.
• W4312129162 cites W2810550076 @default.
• W4312129162 cites W2891953222 @default.
• W4312129162 cites W2896494392 @default.
• W4312129162 cites W2910154923 @default.
• W4312129162 cites W2933733203 @default.
• W4312129162 cites W2944062787 @default.
• W4312129162 cites W2954024999 @default.
• W4312129162 cites W2962669443 @default.
• W4312129162 cites W3037149918 @default.
• W4312129162 cites W3128172506 @default.
• W4312129162 cites W3164033312 @default.
• W4312129162 cites W3187128327 @default.
• W4312129162 cites W4220982605 @default.
• W4312129162 doi "https://doi.org/10.1186/s12885-022-10358-0" @default.
• W4312129162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36544095" @default.
• W4312129162 hasPublicationYear "2022" @default.
• W4312129162 type Work @default.
• W4312129162 citedByCount "2" @default.
• W4312129162 countsByYear W43121291622023 @default.
• W4312129162 crossrefType "journal-article" @default.
• W4312129162 hasAuthorship W4312129162A5018555044 @default.
• W4312129162 hasAuthorship W4312129162A5026480264 @default.
• W4312129162 hasAuthorship W4312129162A5038250239 @default.
• W4312129162 hasAuthorship W4312129162A5041701016 @default.
• W4312129162 hasAuthorship W4312129162A5049515542 @default.
• W4312129162 hasAuthorship W4312129162A5055137050 @default.
• W4312129162 hasAuthorship W4312129162A5060126327 @default.
• W4312129162 hasAuthorship W4312129162A5072689759 @default.
• W4312129162 hasAuthorship W4312129162A5080684289 @default.
• W4312129162 hasAuthorship W4312129162A5083470582 @default.
• W4312129162 hasAuthorship W4312129162A5085561415 @default.
• W4312129162 hasBestOaLocation W43121291621 @default.
• W4312129162 hasConcept C147483822 @default.
• W4312129162 hasConcept C159654299 @default.
• W4312129162 hasConcept C167672396 @default.
• W4312129162 hasConcept C203014093 @default.
• W4312129162 hasConcept C2522874641 @default.
• W4312129162 hasConcept C2776995267 @default.
• W4312129162 hasConcept C2777575956 @default.
• W4312129162 hasConcept C2777607303 @default.
• W4312129162 hasConcept C2777872185 @default.
• W4312129162 hasConcept C2778453870 @default.
• W4312129162 hasConcept C2779338263 @default.
• W4312129162 hasConcept C2781375147 @default.
• W4312129162 hasConcept C70905583 @default.
• W4312129162 hasConcept C71924100 @default.
• W4312129162 hasConcept C8891405 @default.
• W4312129162 hasConceptScore W4312129162C147483822 @default.
• W4312129162 hasConceptScore W4312129162C159654299 @default.
• W4312129162 hasConceptScore W4312129162C167672396 @default.
• W4312129162 hasConceptScore W4312129162C203014093 @default.
• W4312129162 hasConceptScore W4312129162C2522874641 @default.
• W4312129162 hasConceptScore W4312129162C2776995267 @default.
• W4312129162 hasConceptScore W4312129162C2777575956 @default.
• W4312129162 hasConceptScore W4312129162C2777607303 @default.
• W4312129162 hasConceptScore W4312129162C2777872185 @default.
• W4312129162 hasConceptScore W4312129162C2778453870 @default.
• W4312129162 hasConceptScore W4312129162C2779338263 @default.
• W4312129162 hasConceptScore W4312129162C2781375147 @default.
• W4312129162 hasConceptScore W4312129162C70905583 @default.
• W4312129162 hasConceptScore W4312129162C71924100 @default.
• W4312129162 hasConceptScore W4312129162C8891405 @default.
• W4312129162 hasIssue "1" @default.
• W4312129162 hasLocation W43121291621 @default.
• W4312129162 hasLocation W43121291622 @default.

• next